ClinicalTrials.gg
CompletedNCT07063238Updated Jan 29, 2026

A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)

A Phase 1 interventional study of MK-8527 and Moxifloxacin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Researchers are looking for new medicines to prevent Human Immunodeficiency Virus Type 1 (HIV-1) infection. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Medicines to prevent HIV-1 infection are called pre-exposure prophylaxis (PrEP). Some people may have trouble following a PrEP plan because it involves either taking medicine everyday by mouth or getting injections (shots) often.

MK-8527 is a study medicine designed to prevent HIV-1 infection. MK-8527 is different from standard (usual) PrEP because it is taken once a month, by mouth, as a tablet.

The goal of this study is to learn if taking a higher-than-normal dose of MK-8527 increases the QT interval (a measure of heart rhythm) by a certain amount.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has (BMI) between 18 and 32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases.
  • Has history of cancer ().
  • Has positive test(s) for surface antigen (HBsAg), antibodies or (HIV).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    MK-8527 PLUS Moxifloxacin and Placebo

    Participants receive a single dose of MK-8527 followed by a single dose of moxifloxacin and a single dose of placebo depending on randomization.

    Drug: MK-8527 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Moxifloxacin PLUS MK-8527 and Placebo

    Participants receive a single dose of moxifloxacin followed by a single dose of MK-8527 and a single dose of placebo depending on randomization.

    Drug: MK-8527 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Placebo PLUS MK-8527 and Moxifloxacin

    Participants receive a single dose of placebo followed by a single dose of MK-8527 and a single dose of moxifloxacin depending on randomization.

    Drug: MK-8527 · Drug: Moxifloxacin · Drug: Placebo

Interventions

  • Oral administration

  • Oral administration

  • DrugPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Change from Baseline in QT interval corrected for heart rate (QTc) following MK-8527 administration

    Change from Baseline in QTc following MK-8527 administration will be reported.

    Time frame: Baseline and up to approximately 24 hours

Secondary outcomes

  1. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to approximately 7 weeks

  2. Number of participants who discontinue study intervention due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 7 weeks

  3. Change from Baseline in QTc following moxifloxacin administration

    Change from Baseline in QTc following moxifloxacin administration will be reported.

    Time frame: Baseline and up to approximately 24 hours

  4. Area Under the Plasma Concentration-Time curve From Time 0 to 24 hours (AUC0-24) of MK-8527

    Blood samples will be collected at multiple time points to estimate AUC0-24 of MK-8527

    Time frame: At designated timepoints (up to 24 hours postdose)

  5. Area Under the Plasma Concentration-Time curve From Time 0 to 168 hours (AUC0-168) of MK-8527

    Blood samples will be collected at multiple time points to estimate AUC0-168 of MK-8527

    Time frame: At designated timepoints (up to 168 hours postdose)

  6. Area Under the Plasma Concentration-Time curve From Time 0 to infinity (AUC0-inf) of MK-8527

    Blood samples will be collected at multiple time points to estimate AUC0-inf of MK-8527

    Time frame: At designated timepoints (up to approximately 7 weeks)

  7. Maximum plasma concentration (Cmax) of MK-8527

    Blood samples will be collected at multiple time points to estimate Cmax of MK-8527

    Time frame: At designated timepoints (up to approximately 7 weeks)

  8. Time to maximum plasma concentration (Tmax) of MK-8527

    Blood samples will be collected at multiple time points to estimate Tmax of MK-8527

    Time frame: At designated timepoints (up to approximately 7 weeks)

07

Study locations

1 site
  • Hassman Research Institute Marlton Site ( Site 0001)
    Marlton, New Jersey 08053, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Dec 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartActual
Aug 12, 2025
Primary completionActual
Dec 6, 2025
CompletionActual
Dec 29, 2025
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063238
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Aug 12, 2025
Primary completion
Dec 6, 2025
Completion
Dec 29, 2025
Last update
Jan 29, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion